Avanos Medical Stock Down as Q2 Earnings Miss Estimates, Margins Down

Avanos Medical (AVNS) reported Q2 2025 adjusted EPS of $0.17, missing estimates by 5.6% and down 50% year-over-year, despite revenue growing 1.9% to $175 million, which surpassed consensus. The significant earnings miss and 390 basis point contraction in gross margin were primarily driven by $8 million in tariffs and broader cost pressures, leading to a 12.1% decline in the stock. While Specialty Nutrition Systems (SNS) and Radiofrequency Ablation (RFA) sales saw growth, weakness in surgical pain and recovery, coupled with an estimated $15 million in full-year tariff costs, continue to pressure profitability, prompting the company to implement mitigation strategies including divestitures and cost containment.

Analysis

Avanos Medical's second-quarter 2025 results present a challenging picture of severe margin erosion despite modest top-line growth. While revenue increased 1.9% year-over-year to $175 million, beating consensus estimates, this was overshadowed by a 50% decline in adjusted EPS to $0.17, which missed forecasts by 5.6%. The primary driver of this profitability collapse was a 390 basis point contraction in adjusted gross margin and a 580 basis point drop in adjusted operating margin, directly attributed to an $8 million impact from tariffs in the quarter. The company's performance is bifurcated: the Specialty Nutrition Systems (SNS) segment remains a key strength with 5.1% revenue growth, and the radiofrequency ablation (RFA) product line grew a robust 13.7%. However, these bright spots were offset by declines in the surgical pain and recovery unit (-9.4%) and the Corporate segment (-23.1%). In response, management is executing a strategic pivot, divesting the underperforming Hyaluronic Acid line to focus on its core segments and implementing a multi-year plan to mitigate an estimated $15 million in annual tariff costs. The market's reaction was sharply negative, with a 12.1% stock decline that exacerbated its significant 37.9% year-to-date underperformance against both its industry and the S&P 500.

Key Decisions for Investors

• Investors should closely monitor the effectiveness of Avanos's tariff mitigation strategies, as the reiterated full-year guidance appears ambitious given the severe Q2 margin compression and the projected $15 million annual tariff impact.
• Consider the company's bifurcated performance; continued strength in the Specialty Nutrition Systems segment and RFA products may present long-term value, but this is currently overshadowed by weakness in the surgical pain unit and significant external cost pressures.
• Given the stock's 37.9% year-to-date decline and intensely negative market sentiment, a cautious stance is warranted until there is tangible evidence that pricing actions and supply chain shifts can restore profitability.